Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2019 / Jul / Taking Aim at a Moving Target
Oncology Microscopy and imaging Oncology Technology and innovation

Taking Aim at a Moving Target

A new imaging technique allows us to see the evolution of cancerous cells

By Michael Schubert 07/16/2019 Quick Read (pre 2022) 1 min read

Share

How do cancerous tumors form? It’s a question to which we don’t yet have a detailed answer – but one that, if fully explored, could lead to better prevention, diagnosis, and treatment. Using a laboratory model of breast cancer, a team of researchers at the Walter and Eliza Hall Institute of Medical Research in Parkville, Australia, has developed a new imaging technique to observe individual cells within a tumor at high resolution and in three dimensions (1). The approach allows them to observe individual clones descended from a single precancerous cell to see how they change, which become cancerous, and which ones are most changeable or have potential growth or treatment resistance advantages. We spoke to study author Jane Visvader to learn more…

What enabled you to view breast cancer tumors in 3D at such a resolution?

The clearing agent was instrumental in enabling us to simultaneously perform immunolabeling and detect native fluorescence in large portions of tissue or tumors, and in allowing us to gain insight into tissue architecture at single cell resolution.

What's the most interesting discovery revealed by your new imaging technique?

The pipeline involving 3D imaging at high resolution, together with the sorting and sequencing of individual clones, led to the unexpected finding that almost every clone had undergone an epithelial-to-mesenchymal transition (EMT). Although this process has been well-documented in cancers, it was presumed to occur in relatively rare cells, such as those along the leading edge of the tumor, before their extravasation into the bloodstream. In the p53/Pten deletion models we examined, the EMT was widespread and occurred at a clonal level. Of note, the molecular signature changed drastically from an epithelial to mesenchymal state, based not just on a small number of genes, but on hundreds to thousands.

These findings highlight the inherent plasticity of tumor cells and indicate that both epithelial and mesenchymal cells need to be targeted early in tumor progression. It is somewhat alarming that each clone had a propensity to shift towards a different (mesenchymal) state, indicating that cancer cells behave like moving targets.

Credit: Rios, Visvader et al., published in Cancer Cell

What’s next for this research?

Robust markers of the epithelial, mesenchymal, and hybrid cancerous states must be identified to allow more effective targeting – but this is a tough proposition and will require further research.

As it stands, our imaging protocol is simple to use, relies on a non-toxic clearing agent, and can be completed within three days. My colleagues and I hope that it will one day be adapted for use in pathology labs to diagnose and select treatment for specific diseases.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. AC Rios et al., “Intraclonal plasticity in mammary tumors revealed through large-scale single-cell resolution 3D imaging”, Cancer Cell, 35, 953 (2019). PMID: 31185217.

About the Author(s)

Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

More Articles by Michael Schubert

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Intense Intestines
Microscopy and imaging
Intense Intestines

January 19, 2024

1 min read

Some powerful fluorescent microscopy in this Image of the Month…

Context Matters in Cancer Biology
Microscopy and imaging
Context Matters in Cancer Biology

December 27, 2021

1 min read

Akoya is leading the way with spatial phenotypic signatures – a novel class of biomarkers for predicting response to immunotherapy

When Pathology Goes 3D
Microscopy and imaging
When Pathology Goes 3D

February 2, 2022

1 min read

Stratifying cancers with non-destructive 3D pathology

Sacrificing Safety for Speed?
Microscopy and imaging
Sacrificing Safety for Speed?

February 4, 2022

3 min read

Wide adaptation of antigen testing could increase the risk of exposure to infectious SARS-CoV-2 samples

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.